Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more
In a recent paper in EMBO Journal, postdoc Maja Radulovic and her co-workers in Harald Stenmark's group reveal a novel mechanism that promotes cell survival, namely repair of damaged lysosomes.
Work in Harald Stenmark's group has previously shown that a protein machinery known as endosomal sorting complex required for transport (ESCRT) mediates important cellular functions such as lysosomal downregulation of growth factor receptors and sealing of the nascent nuclear envelope during mitotic exit
Now, postdoc Maja Radulovic and her co-workers in Stenmark's group have found that ESCRT proteins repair damaged lysosomes, and that this is essential for cell viability upon lysosomal damage. Compounds that selectively damage lysosomes of cancer cells are in clinical trials as cancer drugs, and the newly discovered mechanism may provide us with tools to increase the efficacy of such drugs.
Although the mechanisms that mediate chromosome condensation have been extensively studied for decades, little is known about the molecular mechanisms that initiate and control chromosome condensation at mitosis entry. Furthermore, how cells discriminate between normal chromosomes and potentially harmful non-chromosomal DNA during mitosis remains mysterious.
A collaborative work by the groups of Jorrit M. Enserink (OuH), Pierre Chymkowitch (OuH) and Yves Barral (ETH, Zurich, Switzerland) suggesting that centromeres play a so-far under-explored role in chromosome condensation and immunity mechanisms is published in Cell and now available online.
The Malmberg Lab is one of four partners in project that recently was awarded 31 MSEK to study and develop new technologies for cancer immunotherapy. The constellation is led by Professor Bjorn Onfelt at the Royal Institute of Technology in Sweden.
The team focus on T and NK cells and their interactions with tumor cells in both 2D and 3D models.
“One of the most exciting things with this collaboration is the interdisciplinary collaboration between biologists, clinical scientists and phycisists”, says Kalle Mamberg, who holds a Visiting Professor position at the Karolinska Institute.
The paper entitled "Light-enhanced VEGF121/rGel: A tumor targeted modality with vascular and immune-mediated efficacy" by Anette Weyergang et al. includes a collaboration with the Rosenblum lab at MD Anderson Cancer Center and the core facility for advanced light microscopy at the Institute for Cancer Research (OUS).
The manuscript was published in Journal of Controlled Release a highly recognized journal in the field of delivery science and technology.